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Heart failure (HF) is a medical problem of huge socioeconomic importance, mainly 
due to the increasing life expectancy in our societies and the strides in the treatment 
of ischemic heart disease which resulted in improved prognosis of our patients. These 
medical and socioeconomic issues may explain why HF poses a significant financial 
burden on our health care systems. It is estimated that acute decompensated HF ac-
counts for 2.% of all emergency room visits, its prevalence is steadily increasing in 
epidemic proportions and in age-dependent manner, reaching an incidence of almost 
10% in patients aged >65 years.1 
There has been considerable improvement in our therapeutic armamentarium 
over the years with significant benefit obtained with use of angiotensin converting 
enzyme inhibitors or angiotensin receptor blockers and β-blockers. However, there is 
still a large population of HF patients who remain refractory to current therapeutic 
approaches and this therapeutic gap has recently been bridged by the newer mode 
of electrical therapy known as cardiac resynchronization therapy (CRT), effected by 
biventricular pacing.2,3 CRT has been shown to improve symptoms and prognosis of 
patients with HF. The pathophysiological rationale for the development of CRT was 
the observation that some patients with advanced HF presented asynchronous contrac-
tion of the left ventricle (LV) on echocardiography. Asynchronous contraction due to 
cardiac conduction abnormalities, often described as cardiac dyssynchrony, reflected 
by the presence of left bundle branch block (LBBB) on the electrocardiogram (ECG), 
occurring in 20-30% of patients afflicted by HF, has been documented to adversely 
affect the function of the failing heart.4 Furthermore, it has been shown that cardiac 
dyssynchrony has an unfavorable influence on prognosis in patients with HF.5,6 
CRT aims to improve the mechanical function of the failing heart. Biventricular 
pacing is an effective way to achieve CRT and restore electromechanical synchrony by 
simultaneously pacing at different sites of the heart, classically at the right ventricular 
apex and the lateral wall of the LV. This is accomplished by inserting the LV pacing 
lead via the coronary sinus and placing it into a lateral cardiac vein tributary. In a 
large number of studies, it is a consistent finding that biventricular pacing increases LV 
ejection fraction (LVEF) and cardiac output and most importantly, improves quality 
of life, functional class and exercise capacity in the majority of the treated patients.7-10 
In terms of pathophysiology, CRT has a unique characteristic among other therapies 
for HF. Its favorable influence on cardiac performance has not been associated with 
increased oxygen consumption, an issue of profound importance especially in patients 
with ischemic cardiomyopathy.11 These striking beneficial effects of CRT, had not 
been accompanied by any detectable survival benefit in the large number of small 
randomized trials that were published during the initial period of biventricular pac-
ing.7-10 Of course, these studies were not designed to detect a survival benefit and thus, 
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they were underpowered to study the effects of biventricular 
pacing on overall mortality. However, the lack of statistical 
significance should not be considered synonymous to the lack 
of clinical significance. In the case of CRT, this fact was firstly 
supported by a meta-analysis of four large randomized trials, 
which showed that CRT therapy significantly reduced all-
cause mortality (relative risk=0.77).12 Thereafter, the results 
of the two randomized studies having as primary end-point 
total mortality, the COMPANION13 and the CARE-HF14 
trials, verified the aforementioned findings and provided the 
necessary evidence for the recommendations and guidelines 
on CRT use for patients with symptomatic HF, which were 
published three years ago by the American Heart Association 
(AHA)/American College of Cardiology (ACC)15 and by the 
European Society of Cardiology (ESC).16
The accumulating evidence from the recently published 
studies resulted in the revised recommendations by the ESC 
and the European Heart Rhythm Association.17 According to 
these recommendations, CRT is considered class I (level of 
evidence A) therapy for the HF patients who remain symp-
tomatic in NYHA classes III–IV despite optimal treatment, 
with LVEF ≤35%, LV dilatation, normal sinus rhythm and 
wide QRS complex (≥120 ms). Although this general classical 
indication includes the majority of patients studied in everyday 
clinical practice, the authors of these guidelines tried to pro-
vide practical answers to a number of problematic unresolved 
clinical issues that raised questions regarding appropriate 
use of CRT.17 Indeed, the authors of the 2007 ESC/EHRS 
guidelines devoted a great effort to analyze these unresolved 
issues which are expected to be enlightened by some large 
ongoing randomized trials (Table 1). 
Thus, trying to provide a reasonable clinical approach to 
these unsolved issues despite the lack of solid evidence, they 
suggested that CRT can be a reasonable therapeutic option 
in HF patients with NYHA classes III–IV symptoms, low 
LVEF ≥35%, LV dilatation and a concomitant indication for 
permanent pacing (first implant or upgrading of conventional 
pacemaker) (Class IIa: level of evidence C). In addition CRT is 
considered appropriate for HF patients with a Class I indica-
tion for an ICD (first implant or upgrading at device change) 
who are symptomatic in NYHA classes III–IV despite optimal 
treatment, with low LVEF ≤35%, LV dilatation and wide 
QRS complex (≥120 ms)(Class I: level of evidence). Finally, 
heart failure patients with permanent atrial fibrillation who 
remain symptomatic in NYHA classes III–IV despite optimal 
treatment, with low LVEF ≤35%, LV dilatation and indication 
for AV junction ablation are considered candidates for CRT 
according to the latest guidelines (Class IIa: level of evidence 
C). A synopsis of the 2008 ESC/EHRA guidelines on CRT 
in comparison to the previous (published at 2005) ACC and 
ESC guidelines is presented at Table 2.
c O m m E N t s  O N  U N s O L v E D  I s s U E s  
A N D  P O t E N t I A L  N E W  I N D I c A t I O N s
CRT is a rapidly evolving therapeutic strategy which is 
expected to be influenced by the accumulation of evidence 
derived by ongoing studies, by the accumulation of increasing 
operator and centers’ experience and by the development of 
new tools and modalities that can be used to achieve biven-
tricular pacing. In this context, the current situation regard-
ing indications and patients’ selection criteria is expected to 
change. Many of the unsolved issues, which are presented in 
Table 1 are now considered as “non-classical indications”. 
Some of them will possibly be included in future widely ac-
cepted indications, while others will be rejected in the light 
of new evidence. Although preliminary data may support the 
so called “non-classical indications” any comments on their 
applicability in everyday clinical practice will inevitably be, at 
least partly, subjective.
Although currently existing evidence from large scale 
studies is based on selection criteria solely related to the 
duration of QRS complex, it is well-known that electrical 
dyssynchrony does not always accompany mechanical dys-
synchrony.18 Taking into consideration that CRT through 
biventricular pacing aims to restore mechanical dyssynchrony, 
we believe that it should be directed only to these patients 
who present both electrical and mechanical dyssynchrony, 
simply because there are no data or even convincing assump-
tions that have associated the beneficial effects afforded by 
biventricular pacing with any other characteristic of patients 
with advanced HF apart from the mechanical dyssynchrony. 
Although preliminary results from the PROSPECT study1 
showed that no echocardiographic measure of mechanical 
dyssynchrony was found to be useful for identifying patients 
more likely to respond to CRT, we should not apply CRT in 
tAbLE 1. Unresolved issues in CRT indications
1. Lack of electromechanical dyssynchrony
2. Narrow QRS on surface ECG
3. Atrial fibrillation
4. Right bundle branch block
5. Indication for permanent pacing in patients with mild heart 
failure or asymptomatic left ventricular systolic dysfunction
6. Patients with a previously implanted conventional pacing device 
and severe left ventricular dysfunction
7. Co-existing right heart failure
8. Heart failure and pacing in the pediatric population
. Planned cardiac surgery and classical CRT indication.
INDICATIONS FOR CRT
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patients who lack electromechanical dyssynchrony given the 
lack of a relevant pathophysiological mechanism that could 
support the notion that improvement of LV function can be 
achieved by biventricular pacing independently of preexisting 
mechanical dyssynchrony.
On the other hand, another “non-classical” indication 
for CRT would be the application of biventricular therapy 
in patients with advanced refractory HF in the absence of 
prolonged QRS duration (<120 ms) but in the presence of 
echocardiographically documented inter- or/and intraventricu-
lar dyssynchrony. Again our enthusiasm should be tempered 
by the lack of convincing evidence. Notably, recently, Beshai 
et al evaluated this issue in a prospective, double-blind, ran-
domized, controlled clinical trial (RethinQ study).21 A total 
of 172 HF patients with a SCD-HeFT indication for ICD, 
NYHA class III functional class, QRS duration <130 ms 
and evidence of mechanical dyssynchrony as measured by 
echocardiography, were randomized to either CRT or no CRT. 
The presence of mechanical dyssynchrony was identified by 
using echocardiographic imaging methods. In 6% of cases 
the tissue Doppler-defined presence of an opposing wall delay 
≥65 ms was used as a qualifying criterion, while the rest 4% of 
patients exhibited a significant mechanical delay in the septal-
to-posterior wall, obtained by M-mode in the parasternal long-
axis view. After 6 months, among 156 patients assessed (76 in 
the CRT and 80 in the control group), CRT was not shown to 
confer any benefit in patients with QRS duration < 120 ms, as 
evidenced by lack of improvement in peak oxygen consump-
tion. However, we should keep in mind that the results of the 
RethinQ study are not conclusive and mostly, underline the 
need for further large-scale prospective, adequately powered, 
double-blind trials that could delineate the potential beneficial 
effect of CRT on the subpopulation of HF patients with nar-
row QRS as well as the optimal echocardiographic imaging 
method which enables the most accurate definition of cardiac 
dyssynchrony and the selection of responders. Amongst others, 
we have suggested20 that until results from these studies are 
available, we should follow the recently published guidelines 
of the ESC/EHRA routinely precluding patients with narrow 
QRS from CRT, even in the case of echocardiographically 
determined cardiac dyssynchrony.
For the first time, the authors of the 2007 ESC/EHRA 
guidelines addressed the dilemma of providing CRT versus 
conventional pacing in patients with indication for permanent 
pacing, with mild heart failure or asymptomatic LV systolic 
dysfunction and the dilemma of CRT in patients with a pre-
viously implanted conventional pacing device and severe LV 
dysfunction. In both cases accumulating data22 suggest that the 
detrimental role of pacing-induced dyssynchrony may justify 
the use of biventricular pacing in these patients. Regrettably, 
the authors of the recent guidelines included advanced NYHA 
class (III-IV) as a perquisite for this indication. However, it 
would be logical to hypothesize that a large proportion of 
NYHA II patients who will be implanted a conventional 
pacemaker or ICD, will deteriorate due to pacing-induced 
dyssynchrony and will need to upgrade to biventricular systems 
with profound consequences on efficacy, safety and cost-ef-
fectiveness of the management of the patient.
In conclusion, the classical indications for CRT have 
evolved considerably, while the non-classical should not be 
tAbLE 2. CRT guidelines in chronic heart failure patients according to the recently published ESC/EHRA recommen-
dations in comparison to the guidelines published in 2005 by the ACC/AHA and by the ESC.
Patients’ characteristics clinical end-point class and level 
of evidence
ref.
ACC/AHA Guideline 
Update for Chronic 
Heart Failure 
(2005 update)
NYHA class III-IV
LVEF ≤35%
Sinus rhythm
Symptoms despite optimal medical therapy
Cardiac dyssynchrony (currently defined as QRS >0.12 ms)
Symptoms, 
Hospitalizations, 
Mortality
I (A) 15
ESC guidelines for 
Chronic Heart Failure 
(2005 update)
NYHA class III-IV
Reduced LVEF
Symptoms despite optimal medical therapy
Cardiac dyssynchrony (QRS>0.12 ms)
Symptoms, 
Hospitalizations
I (A) 16
Mortality I (B) 16
ESC/EHRA guidelines 
for pacing and CRT 
(2007)
NYHA class III-IV
LVEF ≤35%
Symptoms despite optimal medical therapy
Wide QRS complex (QRS>0.12 ms)
Morbidity and 
Mortality
I (A) 17
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routinely included in everyday clinical practice, despite the 
fact that they may represent reasonable therapeutic options 
in selected cases.
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